{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:36:04Z","timestamp":1747157764180,"version":"3.40.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clgc.2024.102108","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T03:43:18Z","timestamp":1714534998000},"page":"102108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET\/CT"],"prefix":"10.1016","volume":"22","author":[{"given":"Miles","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-1735","authenticated-orcid":false,"given":"Xinhe","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-283X","authenticated-orcid":false,"given":"Rebecca","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5567-4526","authenticated-orcid":false,"given":"Arun","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ning","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Christodouleas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-738X","authenticated-orcid":false,"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel U.","family":"Takvorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Vapiwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin R.","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-7968","authenticated-orcid":false,"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.clgc.2024.102108_bib0001","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2024.102108_bib0002","series-title":"Management of Advanced Prostate Cancer","article-title":"Adjuvant and salvage radiation therapy for prostate cancer after radical prostatectomy","author":"Lee","year":"2018"},{"issue":"17","key":"10.1016\/j.clgc.2024.102108_bib0003","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1002\/cncr.25993","article-title":"Salvage radiation in men after prostate-specific antigen failure and the risk of death","volume":"117","author":"Cotter","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2024.102108_bib0004","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.291.11.1325","article-title":"Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy","volume":"291","author":"Stephenson","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clgc.2024.102108_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.eururo.2017.01.039","article-title":"Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102108_bib0006","first-page":"493","article-title":"Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis","volume":"19","author":"Jia","year":"2016","journal-title":"Asian J Androl"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.eururo.2017.10.009","article-title":"Multi-institutional evaluation of elective nodal irradiation and\/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer","volume":"74","author":"Ramey","year":"2018","journal-title":"Eur Urol"},{"issue":"9858","key":"10.1016\/j.clgc.2024.102108_bib0008","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clgc.2024.102108_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.23736\/S0393-2249.18.03124-7","article-title":"Salvage radiation therapy after radical prostatectomy: survival analysis","volume":"71","author":"Galla","year":"2019","journal-title":"Minerva Urol Nefrol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cncr.27712","article-title":"Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy","volume":"119","author":"Moghanaki","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2024.102108_bib0011","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00066-015-0872-9","article-title":"Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: a propensity score-matched analysis","volume":"191","author":"Song","year":"2015","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0012","first-page":"54","article-title":"Radiotherapy after porostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk Patients","volume":"69","author":"Spiotto","year":"2007","journal-title":"IJROBP"},{"key":"10.1016\/j.clgc.2024.102108_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-019-1301-5","article-title":"Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer\u2014a retrospective analysis of dose-escalated patients","volume":"14","author":"Link","year":"2019","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102108_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3816\/CGC.2004.n.018","article-title":"Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy","volume":"3","author":"Kim","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.clgc.2024.102108_bib0015","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet North Am Ed"},{"issue":"7","key":"10.1016\/j.clgc.2024.102108_bib0016","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41585-022-00614-0","article-title":"ADT and node inclusion improves salvage radiation","volume":"19","author":"Romero","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"10356","key":"10.1016\/j.clgc.2024.102108_bib0017","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(22)01440-4","article-title":"The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy","volume":"400","author":"Ghadjar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clgc.2024.102108_bib0018","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"(68)Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.clgc.2024.102108_bib0019","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","article-title":"Prospective comparison of whole-body MRI and (68)Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy","volume":"46","author":"Sawicki","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clgc.2024.102108_bib0020","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2967\/jnumed.119.234799","article-title":"(18)F-DCFPyL PET\/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy","volume":"61","author":"Mena","year":"2020","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.clgc.2024.102108_bib0021","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00259-022-05693-0","article-title":"Diagnostic accuracy of [(18)F]PSMA-1007 PET\/CT in biochemical recurrence of prostate cancer","volume":"49","author":"Mingels","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2024.102108_bib0022","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clgc.2024.102108_bib0023","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102108_bib0024","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2967\/jnumed.121.262347","article-title":"Predictors of (18)F-DCFPyL PET\/CT positivity in patients with biochemical recurrence of prostate cancer after local therapy","volume":"63","author":"Mena","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0025","first-page":"1","article-title":"Contemporary role of the decipher(R) test in prostate cancer management: current practice and future perspectives","volume":"18","author":"Dalela","year":"2016","journal-title":"Rev Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102108_bib0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bjmsu.2011.08.006","article-title":"PSA velocity and doubling time in diagnosis and prognosis of prostate cancer","volume":"5","author":"Vickers","year":"2012","journal-title":"Br J Med Surg Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0027","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.juro.2016.07.004","article-title":"prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy","volume":"197","author":"Liesenfeld","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102108_bib0028","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/1097-0142(19930901)72:5<1709::AID-CNCR2820720535>3.0.CO;2-O","article-title":"Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy","volume":"72","author":"Zagars","year":"1993","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0029","first-page":"1","article-title":"Comparing stepwise regression models to the best-subsets comparing stepwise regression models to the best-subsets models, or, the art of stepwise models, or, the art of stepwise","volume":"42","author":"Ruengvirayudh","year":"2016","journal-title":"Gen Linear Model J"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/fmch-2019-000262","article-title":"Variable selection strategies and its importance in clinical prediction modelling","volume":"8","author":"Chowdhury","year":"2020","journal-title":"FMCH"},{"issue":"2","key":"10.1016\/j.clgc.2024.102108_bib0031","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2017.10.022","article-title":"Delineating sites of failure following post-prostatectomy radiation treatment using (68)Ga-PSMA-PET","volume":"126","author":"Byrne","year":"2018","journal-title":"Radiother Onco"},{"key":"10.1016\/j.clgc.2024.102108_bib0032","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2022.08.035","article-title":"Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation","volume":"170","author":"Imber","year":"2022","journal-title":"Urology"},{"issue":"13","key":"10.1016\/j.clgc.2024.102108_bib0033","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1158\/1078-0432.CCR-21-0749","article-title":"How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?","volume":"27","author":"True","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102108_bib0034","article-title":"Performance of 18F-DCFPyL PET\/CT imaging in early detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102108_bib0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2967\/jnumed.116.185538","article-title":"PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer","volume":"58","author":"Dietlein","year":"2017","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.clgc.2024.102108_bib0036","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/pros.21420","article-title":"Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum","volume":"72","author":"Briganti","year":"2012","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.clgc.2024.102108_bib0037","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-10-3277","article-title":"Significance and mechanism of lymph node metastasis in cancer progression","volume":"71","author":"Kawada","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clgc.2024.102108_bib0038","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2017.12.023","article-title":"Intermediate endpoints after postprostatectomy radiotherapy: 5-year distant metastasis to predict overall survival","volume":"74","author":"Jackson","year":"2018","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102108_bib0039","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1001\/jama.291.11.1380","article-title":"Salvage radiotherapy for recurrent prostate cancer: the earlier the better","volume":"291","author":"Anscher","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clgc.2024.102108_bib0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2011.10.010","article-title":"Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy","volume":"61","author":"Stephenson","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102108_bib0041","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.juro.2014.08.096","article-title":"Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy","volume":"193","author":"Tilki","year":"2015","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102108_bib0042","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.eururo.2015.04.035","article-title":"Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival","volume":"68","author":"Nini","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102108_bib0043","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2967\/jnumed.117.202945","article-title":"Impact of (68)Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.102108_bib0044","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bju.13926","article-title":"Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study","volume":"121","author":"Tumati","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2024.102108_bib0045","article-title":"Efficacy and toxicity of whole pelvic radiotherapy versus prostate-only radiotherapy in localized prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102108_bib0046","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ijrobp.2009.08.043","article-title":"Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer","volume":"78","author":"Deville","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0047","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2015.11.020","article-title":"Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation","volume":"118","author":"Sini","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102108_bib0048","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.juro.2009.11.039","article-title":"The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era","volume":"183","author":"Boorjian","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0049","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1442-2042.2008.02144.x","article-title":"Salvage radiotherapy following radical prostatectomy","volume":"16","author":"Chalasani","year":"2009","journal-title":"Int J Urol"},{"issue":"15","key":"10.1016\/j.clgc.2024.102108_bib0050","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102108_bib0051","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/bju.15724","article-title":"Pathological predictors of 18F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy","volume":"130","author":"Perry","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2024.102108_bib0052","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet North Am Ed"},{"issue":"13","key":"10.1016\/j.clgc.2024.102108_bib0053","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102108_bib0054","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102108_bib0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1148\/radiol.220218","article-title":"(18)F-DCFPyL PET\/CT for initially diagnosed and biochemically recurrent prostate cancer: prospective trial with pathologic confirmation","volume":"305","author":"Ulaner","year":"2022","journal-title":"Radiology"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T08:33:12Z","timestamp":1718526792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S155876732400079X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102108","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET\/CT","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102108"}}